Schedule 13D ownership disclosure
REGENERX BIOPHARMACEUTICALS CO
Security class unavailable · CUSIP: 75886X108
Event date: 2020-10-15
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 34.4000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-20-031744
- Form type
- SC 13D
- Filer
- Essetifin SPA
- CIK
- CIK 1092601
- Filed
- Oct 16, 2020
- Reporting period
- Oct 15, 2020
- Description
- Schedule 13D beneficial ownership